Clinical analysis of operation combined chemotherapy for stage IIIa non-small cell lung cancer.
- Author:
Wei WANG
1
;
Hui LI
;
Li-qun SHANG
;
Xue-chang LI
;
Jun LI
;
Wei-an SONG
;
Feng WEN
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Carcinoma, Non-Small-Cell Lung; drug therapy; mortality; pathology; surgery; Combined Modality Therapy; Female; Humans; Lung Neoplasms; drug therapy; mortality; pathology; surgery; Male; Middle Aged; Neoplasm Staging; Pneumonectomy; methods; Retrospective Studies; Survival Rate; Treatment Outcome
- From: Chinese Journal of Surgery 2005;43(22):1450-1452
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the therapeutic result of operation combined chemotherapy for stage IIIa non-small cell lung cancer.
METHODSFrom January 2000 to December 2003, the data of 83 cases with stage IIIa non-small cell lung cancer undergoing operation combined chemotherapy and 33 cases with stage IIIa non-small cell lung cancer undergoing non-operative therapy were retrospectively analyzed. The median survival time and the 1-, 2-, 3- year survival rates of the two groups were compared by the Kaplan-Meier method.
RESULTSThe median survival time of the operation group was 20.3 months, and the 1-, 2-, 3- year survival rates were 85%, 70%, and 35% respectively. The median survival time of the non-operation group was 14.5 months and the 1-, 2-, 3- year survival rates were 75%, 33%, and 15% respectively.
CONCLUSIONThe therapeutic result of the operation combined chemotherapy for the stage IIIa non-small cell lung cancer is better than that of the non-operative therapy obviously.
